Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 5/20 | 0.39 |
| ▸ | BMP1 | P13497 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2152151 | 0.78 | CA1 (0.43) | — | |
| SCHEMBL820089 | 0.74 | ALDH1A1 (0.47) | SLC6A4CASR | |
| SCHEMBL20647149 | 0.72 | CA12 (0.45) | — | |
| SCHEMBL7705711 | 0.72 | ALDH1A1 (0.48) | SLC6A4CASR | |
| SCHEMBL19203475 | 0.71 | SLC6A4 (0.41) | SLC6A4CASR | |
| SCHEMBL6492647 | 0.71 | ALDH1A1 (0.52) | — | |
| SCHEMBL7382719 | 0.71 | ALDH1A1 (0.44) | SLC6A4CASR | |
| SCHEMBL536861 | 0.71 | ALDH1A1 (0.47) | SLC6A4CASR | |
| SCHEMBL820090 | 0.71 | ALDH1A1 (0.47) | SLC6A4CASR | |
| SCHEMBL5610397 | 0.71 | ALDH1A1 (0.47) | SLC6A4CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | SLC6A4 4316/4885CASR 417/4885BMP1 4078/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | SLC6A4 4062/4885CASR 1197/4885BMP1 4389/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | SLC6A4 4316/4885CASR 417/4885BMP1 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.